Research Article

Competitive Risk Model for Specific Mortality Prediction in Patients with Bladder Cancer: A Population-Based Cohort Study with Machine Learning

Hao Su,¹ Xiaoqiang Xue,¹ Yutao Wang,¹ Yi Lu,¹ Chengquan Ma,¹ Zhigang Ji,¹ and Xiaozhe Su²

¹Department of Urology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China
²Department of Urology, Renmin Hospital of Wuhan University, Wuhan 430060, China

Correspondence should be addressed to Zhigang Ji; jizhiganguro@126.com

Received 20 May 2022; Revised 16 June 2022; Accepted 4 July 2022; Published 25 August 2022

1.Introduction

Bladder cancer is a malignancy that occurs in the bladder mucosa. In terms of incidence rate, it is only slightly lower than prostate cancer, making it the second most prevalent malignancy invading the urinary system. The Global Cancer Observatory (GLOBOCAN), a report produced by the World Health Organization, estimates that bladder cancer represents about 3% of all cancer diagnoses globally, with the highest proportion occurring in industrialized countries. In male, bladder cancer has been identified to be the sixth most prevalent malignancy [1]. The American Cancer Society reported that in 2022, there were approximately 81180 newly diagnosed cases of bladder cancer in the United States (U.S.), of which 61700 were male, ranking fourth in new cases of male cancer, and the estimated number of bladder cancer-caused deaths was about 17100, of which 12120 were male [2]. Most of the bladder cancer cases are urothelial carcinomas in pathological classification, and a few are squamous cell carcinomas and other pathological types [3]. Bladder cancer can be categorized into two subtypes: myometrial invasive bladder cancer (MIBC) and non-muscle-invasive bladder cancer (NMIBC), with the latter attributed to roughly 75% of the patients. Half of the NMIBCs are of low
pathological differentiation, whereas most of MBCs are of high atypia [4, 5]. Smoking and occupational exposure to carcinogens (such as aromatic amines, polycyclic aromatic hydrocarbons, and chlorinated hydrocarbons) are important risk factors for bladder cancer [6]. Bladder cancer can pose a heavy social and economic burden on patients and remains a great challenge for global public health [7].

Identification of risk factors for cancer death and non-cancer death is crucial for individualized cancer treatment. Noncancer death is also an important cause of death in cancer patients [8]. Studies have found that multiple noncancer factors, including those concomitant with other cancers, circulatory diseases, non-disease causes, other noncancer diseases, and respiratory diseases, also largely contributed to the deaths of bladder cancer patients, and the proportion of noncancer causes is increasing. Therefore, management of other complications is critical when treating bladder cancer patients [9]. Conventional prediction analyses for the prognosis, recurrence, survival, and mortality of bladder cancer depend upon the number of cancer sites, cancer size, recurrence rate, pathological types, in situ cancer, and TNM stages, which cannot provide predictions that are individualized, precise, and applicable for the patients [10, 11]. As a statistical model-based prediction method, the nomogram has some remarkable merits compared with other approaches and could produce a more scientific prognostic prediction for bladder cancer patients [12, 13].

The goal of this research was to build a competitive risk model for the prediction of noncancer deaths among bladder cancer patients and evaluate its predictive accuracy based on the SEER database, so as to provide a reference for clinical decisions.

2. Methods

2.1. Data Source. We collected clinicopathological data from patients who registered in the SEER program of the National Cancer Institute. SEER is a publicly accessible database that collects clinical, demographic, and outcome data of patients with all types of malignancies, with 18 registries covering 30% of the U.S. population. All the data used in this study followed the specifications of the SEER database. No interventions or patients’ privacy were involved in this study, so ethical approval and informed consent were not needed.

Patients with bladder cancer who registered from 2010 to 2015 were identified in accordance with the third version of the International Classification of Diseases for Oncology (ICD-O-3). Collected clinicopathological information mainly included age (age at diagnosis), marriage (marital status at diagnosis), sex (male or female), race (race recode (white, black, other)), primary (primary site-labeled), grade (grade), behave (ICD-O-3 hist/behave), stage (derived AJCC stage group 7th ed (2010–2015)), T (derived AJCC T 7th ed (2010–2015)), N (derived AJCC N 7th ed (2010–2015)), M (derived AJCC M 7th ed (2010–2015)), surgery (RX Summ-surg prim site (1998+)), chemotherapy (chemotherapy recode (yes, no/unk)), radiation (radiation sequence with surgery), positive (regional nodes positive (1988+)), bone (SEER combined mets at DX-bone (2010+)), brain (SEER combined mets at DX-brain (2010+)), liver (SEER combined mets at DX-liver (2010+)), lung (SEER combined mets at DX-lung (2010+)), size (CS tumor size (2004–2015)), number (total number of in situ/malignant tumors for patient), time (survival months), and status (COD to site rec KM).

2.2. Data Exclusion Criteria. Although SEER includes a large number of cancer records, but there are still many missing values in the registration process. Interpolation could be difficult when there is a large proportion of missing values. Therefore, patients meeting the following criteria were excluded:

(1) Age at diagnosis less than 18 years old
(2) Marital status at diagnosis unavailable
(3) Race unknown
(4) Derived AJCC stage group coded as NA or UNK stage
(5) Cancer stages unknown
(6) Regional nodes positive (1988+) coded as 99
(7) CS tumor size (2004–2015) coded as 999
(8) Survival months was 0
(9) SEER combined mets at DX-bone (2010+) coded as unknown or N/A
(10) SEER combined mets at DX-brain (2010+) coded as unknown or N/A
(11) SEER combined mets at DX-liver (2010+) coded as unknown or N/A
(12) SEER combined mets at DX-lung (2010+) coded as unknown or N/A

After screening the collected data, 39285 patients were recruited for this analysis.

2.3. Data Analysis. Patients who died of bladder cancer were set as events of interest, those who died of other causes were set as competitive events, and survival or loss to follow-up as deletion events.

Before modeling, nonrepetitive random sampling was conducted according to the common 7:3 ratio in the risk model to generate the training as well as the validation cohorts. First, the random forest method was used to calculate the importance of clinical variables in the training cohort, the variables with high importance were used in the subsequent study of the competitive risk model. Subsequently, the univariate competitive risk model was used in the training cohort, and multivariable analysis was carried out on variables with P values less than 0.1 [14]. Then, variables with p < 0.1 in multivariate analysis were selected to construct the predictive nomogram of bladder cancer-specific mortality. A competitive risk model for bladder cancer-specific mortality was constructed, and a predictive nomogram was plotted.

To examine the prediction performance (accuracy) of the model, we utilized the c-statistic and calibration curve. The R
3. Results

3.1. Clinical Characteristics of Included Patients. There were 108884 patients identified who received bladder cancer diagnoses between 2010 and 2015. After screening by eligibility requirements, 39285 patients were incorporated, with the longest follow-up period of 83 months and the median period of follow-up of 29 months. There were 13086 patients who died, among whom 6571 died of bladder cancer and 6515 of other causes. Patients were allotted at random to either the training cohort (n = 27500) or the validation cohort (n = 11785). The patients had a mean age of 70.82 ± 11.84 years old. Among them, 24669 (62.79%) were married, 29573 (75.28%) males, and 35133 (89.43%) were white. There were 37443 patients (95.31%) who had no regional lymph node biopsy or negative biopsy results. As for the primary cancer site, there were 12142 (30.91%) on bladder NOS and 9833 (25.03%) on the lateral wall of the bladder. There were 18240 (46.43%) patients with grade IV cancer and 9797 (24.94%) with grade II. The number of papillary transitional cell carcinomas was 26737 (68.06%). For cancer stages, 16978 patients (43.22%) were in stage 0a or Ois, and 9963 patients (25.36%) were in stage I. For surgery of the primary site, 25288 patients (64.37%) underwent excisional biopsy. For cancer size, 15060 patients (38.34%) had tumor sizes of less than 3 cm. As for the number of tumors, 25415 patients (64.69%) were diagnosed with a single tumor. Table 1 presents the detailed clinical features of the patients who were included in the research.

3.2. Clinical Variables Determination by Random Forest in Train Cohort. The RandomForest packages were applied to evaluate the importance of the clinical variables, and the random seed was set as 123. Age, primary, surgery, size, and grade were considered to be characteristic representative variables in the training cohort, and their importance parameters of random forest screening are shown in Figure 1.

3.3. Construction of the Competitive Risk Model. The five clinical variables that affect the importance close to 0 in the random forest were excluded, and the univariate and multivariate analyses were performed on the remaining clinical variables. We constructed a univariate competitive risk model in the training cohort, and the results showed that all variables were statistically significant (p < 0.1). All parameters in this univariate model were incorporated into the multivariate competitive risk model, and the results showed that age at diagnosis, marital status at diagnosis, sex, primary site-labeled, grade, ICD-O-3 hist/behav, derived AJCC stage group 7th ed (2010–2015), derived AJCC T 7th ed (2010–2015), RX Summ-surg prim site (1998+), chemotherapy recode (yes, no/unk), CS tumor size (2004–2015), and total number of in situ/malignant tumors for patients were independent risk indicators for bladder cancer-specific mortality. Therefore, we incorporated the above variables to construct a competitive risk model for predicting tumor-specific mortality (Table 2; Figures 2 and 3).

3.4. Model Validation. The C index was adopted to assess the accuracy of training and validation cohorts in the model. In the training cohort, the model predicted that the overall C index of patients was 0.876, and the areas under the ROC curve (AUC) were 0.891, 0.871, and 0.853 correspondingly for 1-, 3-, and 5-year cancer-specific mortality. In the validation cohort, the overall C index of patients was 0.877, and the AUC values were 0.894, 0.870, and 0.847 correspondingly for 1-, 3-, and 5-year cancer-specific mortality, which indicated that the model was of great prediction performance. The details are shown in Figure 4 and Figure 5. In addition, the calibration curve of the model illustrated that the anticipated value of the model was almost identical to the actual observation value, illustrating the considerable accuracy of the model.

4. Discussion

Bladder cancer is a prevalent malignancy in the urinary system with its incidence rate only second to that of prostate cancer, presenting a great threat to public health. Currently, individualized cancer treatment has been taken more seriously, and accurate prediction of the survival, prognosis, and mortality of bladder cancer patients is of great importance. Conventional survival analyses (e.g., the Cox proportional hazards model and the Kaplan–Meier marginal regression) usually include only one endpoint event, such as death. However, when there are multiple events and these events compete with each other, the use of a single endpoint analysis would lead to deviations in the anticipated probability of endpoint events. In this research, we employed a competitive risk model to evaluate the risk variables that affect bladder cancer patients’ prognoses. Although this model accounts for bladder cancer-related mortality, it also takes into consideration the deaths attributed to other forms of cancer as well as other events.

Nomograms for prognosis prediction of bladder cancer are drawing increasing attention recently. There have been plenty of studies that applied nomograms to anticipate the overall survival (OS) of bladder cancer patients. Zhan et al. plotted a nomogram that was highly differentiated and accurate and constructed a relevant risk categorization system to anticipate the cancer-specific survival probability for MIBC patients who underwent partial cystectomy [16]. Zhan et al. also constructed a nomogram to provide an accurate prognostic prediction for cancer-specific survival probability in patients with lymph node-positive bladder cancer [17]. Tao et al. created a prognostic nomogram to anticipate the OS in patients with distant-metastatic bladder cancer (DMBC) [18]. Wang et al. applied a nomogram to...
### Table 1: Clinical features of the patients.

| Factors                  | Training cohort \((N = 27500)\) | Validation cohort \((N = 11785)\) | All data \((N = 39285)\) |
|--------------------------|----------------------------------|----------------------------------|--------------------------|
| Age                      | 70.81 ± 11.84                    | 70.85 ± 11.83                    | 70.82 ± 11.84            |
| **Marriage**             |                                  |                                  |                          |
| Married                  | 17338 (63.05)                    | 7331 (62.21)                     | 24669 (62.79)            |
| Single                   | 3257 (11.84)                     | 1395 (11.84)                     | 4652 (11.84)             |
| Widowed                  | 4056 (14.75)                     | 1752 (14.87)                     | 5808 (14.78)             |
| Divorced and others      | 2849 (10.36)                     | 1307 (11.09)                     | 4156 (10.58)             |
| **Sex**                  |                                  |                                  |                          |
| Female                   | 6780 (24.65)                     | 2932 (24.88)                     | 9712 (24.72)             |
| Male                     | 20720 (75.35)                    | 8853 (75.12)                     | 29573 (75.28)            |
| **Race**                 |                                  |                                  |                          |
| White                    | 24597 (89.44)                    | 10536 (89.4)                     | 35133 (89.43)            |
| Black                    | 1597 (5.81)                      | 692 (5.87)                       | 2289 (5.83)              |
| Other                    | 1306 (4.75)                      | 557 (4.73)                       | 1863 (4.74)              |
| **Positive**             |                                  |                                  |                          |
| No nodes/Negative        | 26222 (95.35)                    | 11221 (95.21)                    | 37443 (95.31)            |
| Positive                 | 1278 (4.65)                      | 564 (4.79)                       | 1842 (4.69)              |
| **Primary**              |                                  |                                  |                          |
| **Bladder, NOS**         |                                  |                                  |                          |
| Lateral wall of bladder  | 6831 (24.08)                     | 3002 (25.47)                     | 9833 (25.03)             |
| Overlapping lesion of bladder | 3416 (12.42)                 | 1408 (11.95)                     | 4824 (12.28)             |
| Posterior wall of bladder | 2990 (10.87)                    | 1271 (10.78)                     | 4261 (10.85)             |
| Others                   | 5744 (20.89)                     | 2481 (21.05)                     | 8225 (20.94)             |
| **Grade**                |                                  |                                  |                          |
| Grade I                  | 3281 (11.93)                     | 1444 (12.25)                     | 4725 (12.03)             |
| Grade II                 | 6854 (24.92)                     | 2943 (24.97)                     | 9797 (24.94)             |
| Grade III                | 4555 (16.56)                     | 1968 (16.7)                      | 6523 (16.6)              |
| Grade IV                 | 12810 (46.58)                    | 5430 (46.08)                     | 1824 (46.43)             |
| **Behaviour**            |                                  |                                  |                          |
| Papillary transitional cell carcinoma | 18727 (68.1)          | 8010 (67.97)                     | 26737 (68.06)            |
| Transitional cell carcinoma | 7284 (26.49)             | 3139 (26.64)                     | 10423 (26.53)            |
| Others                   | 1489 (5.41)                      | 636 (5.4)                        | 2125 (5.41)              |
| **Stage**                |                                  |                                  |                          |
| <I                       | 11834 (43.03)                    | 5144 (43.65)                     | 16978 (43.22)            |
| I                        | 6983 (25.39)                     | 2980 (25.29)                     | 9963 (25.36)             |
| II                       | 4286 (15.59)                     | 1869 (15.86)                     | 6155 (15.67)             |
| III                      | 1903 (6.92)                      | 738 (6.26)                       | 2641 (6.72)              |
| IV                       | 2494 (9.07)                      | 1054 (8.94)                      | 3548 (9.03)              |
| **T**                    |                                  |                                  |                          |
| T0 and others            | 11889 (43.23)                    | 5163 (43.81)                     | 17052 (43.41)            |
| T1                       | 7168 (26.07)                     | 3058 (25.95)                     | 10226 (26.03)            |
| T2                       | 5059 (18.4)                      | 2205 (18.71)                     | 7264 (18.49)             |
| T3                       | 2145 (7.8)                       | 891 (7.56)                       | 3036 (7.73)              |
| T4                       | 1239 (4.51)                      | 468 (3.97)                       | 1707 (4.35)              |
| **N**                    |                                  |                                  |                          |
| N0 and others            | 25670 (93.35)                    | 10978 (93.15)                    | 36648 (93.29)            |
| N1                       | 704 (2.56)                       | 312 (2.65)                       | 1016 (2.59)              |
| N2                       | 901 (3.28)                       | 402 (3.41)                       | 1303 (3.32)              |
| N3                       | 225 (0.82)                       | 93 (0.79)                        | 318 (0.81)               |
| **M**                    |                                  |                                  |                          |
| M0                       | 26578 (96.65)                    | 11429 (96.98)                    | 38007 (96.75)            |
| M1                       | 922 (3.35)                       | 356 (3.02)                       | 1278 (3.25)              |
| **Surgery**              |                                  |                                  |                          |
| Surg1                    | 17746 (64.53)                    | 7542 (64)                        | 25288 (64.37)            |
| Surg2                    | 3846 (13.99)                     | 1709 (14.5)                      | 5555 (14.14)             |
| Surg3                    | 1446 (5.26)                      | 597 (5.07)                       | 2043 (5.2)               |
| Surg4                    | 2035 (7.4)                       | 923 (7.83)                       | 2958 (7.53)              |
| Others                   | 2427 (8.83)                      | 1014 (8.6)                       | 3441 (8.76)              |
predict the influence of previous cancer on the OS rate of bladder cancer patients [19]. Yang et al. plotted a prognostic nomogram to anticipate cancer-specific survival in patients with bladder urothelial carcinoma following radical cystectomy [20]. Many other studies have also constructed nomograms of overall survival in patients with bladder cancer [21, 22].

A nomogram to anticipate individual cancer-specific mortality was established in this research premised on a sizable cohort of bladder cancer patients from the SEER database. The nomogram was constructed based on demographic, pathological, and surgical data, which showed remarkable effects in both the training and the validation cohorts, illustrating that the nomogram is of clinical applicability for predicting bladder cancer-specific mortality. Our model contained the following variables produced from clinical practice: age at diagnosis, marital status at diagnosis, sex, primary site-labeled, grade, ICD-O-3 hist/behav, derived AJCC stage group 7th ed (2010–2015), derived AJCC T 7th ed (2010–2015), RX Summ-surg prim site (1998+), chemotherapy recode (yes, no/unk), CS tumor size (2004–2015), the total number of in situ/malignant tumors for patients, in which age was a significant risk variable for the bladder cancer-specific mortality, suggesting that the risk of death in bladder cancer patients would increase significantly with age. Prognostic analyses for bladder cancer conducted by other studies also showed that age played a crucial role in cancer death, and the death rate in patients increased with the increase of age at diagnosis [23, 24]. Another risk factor appeared to be sex. Female bladder cancer patients experienced a poorer prognosis in contrast with males, which was consistent with the results of other studies that found female patients with bladder urothelial carcinoma had higher cancer-specific mortality [25, 26]. The cancer stage was also proved to be a substantial risk indicator for the prognosis of bladder cancer. Upgrading of the stage was associated with a worse prognosis, which was also consistent with many other studies. Cancer T staging was an important part of the model. Many research reports illustrated that bladder invasion depth was strongly linked to bladder cancer patients’ prognoses. With the progress of T staging, cancer would be more invasive and progressive [27]. On the other hand, the prognosis of bladder cancer patients with distant organ metastasis was highly unfavorable in contrast with those without metastasis. Studies showed that different distant metastasis sites had different effects on mortality, and the mortality of patients with multiple distant metastasis sites was significantly higher than those with single distant metastasis sites [28, 29]. Furthermore, the nomogram also illustrated that an increase in cancer size resulted in a poorer prognosis in bladder cancer patients. Other studies have further confirmed the influence of cancer size on bladder cancer-specific prognosis [30]. Moreover, the number of cancers is also related to the prognosis of bladder cancer. Patients with multiple bladder cancer had a poorer prognosis than those with single bladder cancer.

### Table 1: Continued.

| Factors          | Training cohort (N = 27500) | Validation cohort (N = 11785) | All data (N = 39285) |
|------------------|-----------------------------|-------------------------------|----------------------|
| **Radiation**    |                             |                               |                      |
| Others           | 1636 (5.95)                 | 659 (5.59)                    | 2295 (5.84)          |
| No radiation     | 25864 (94.05)               | 11126 (94.41)                 | 36990 (94.16)        |
| **Chemotherapy** |                             |                               |                      |
| Yes              | 9288 (33.77)                | 3874 (32.87)                  | 13162 (33.5)         |
| No               | 18212 (66.23)               | 7911 (67.13)                  | 26123 (66.5)         |
| **Bone**         |                             |                               |                      |
| No               | 27193 (98.88)               | 11669 (99.02)                 | 38862 (98.92)        |
| Yes              | 307 (1.12)                  | 116 (0.98)                    | 423 (1.08)           |
| **Brain**        |                             |                               |                      |
| No               | 27474 (99.91)               | 11775 (99.92)                 | 39249 (99.91)        |
| Yes              | 26 (0.09)                   | 10 (0.08)                     | 36 (0.09)            |
| **Liver**        |                             |                               |                      |
| No               | 27327 (99.37)               | 11713 (99.39)                 | 39040 (99.38)        |
| Yes              | 173 (0.63)                  | 72 (0.61)                     | 245 (0.62)           |
| **Lung**         |                             |                               |                      |
| No               | 27176 (98.82)               | 11658 (98.92)                 | 38834 (98.85)        |
| Yes              | 324 (1.18)                  | 127 (1.08)                    | 451 (1.15)           |
| **Size**         |                             |                               |                      |
| <3               | 10526 (38.28)               | 4534 (38.47)                  | 15060 (38.34)        |
| 3–5              | 8123 (29.54)                | 3502 (29.72)                  | 11676 (29.59)        |
| 5–10             | 7122 (25.9)                 | 2975 (25.24)                  | 10097 (25.7)         |
| ≥10              | 1729 (6.29)                 | 774 (6.57)                    | 2503 (6.37)          |
| **Number**       |                             |                               |                      |
| 1                | 17821 (64.8)                | 7594 (64.44)                  | 25415 (64.69)        |
| >1               | 9679 (35.2)                 | 4191 (35.56)                  | 13870 (35.31)        |

Surgery 1 to 4 denote, respectively: excisional biopsy, electrocautery, radical cystectomy plus ileal conduit, and radical cystectomy (female only); anterior exenteration.
Figure 1: Important parameters of the clinical variables by random forest.

Table 2: Univariate and multivariate competitive risk model.

| Factors   | Univariate analysis | Multivariate analysis |
|-----------|---------------------|-----------------------|
|           | HR (95%CI)          | Z         | P       | HR (95%CI)          | Z         | P       |
| Age       | 1.02(1.02–1.03)     | 16.4      | <0.001  | 1.024(1.021–1.027)  | 15.152    | <0.001  |
| Marriage  | 1.16(1.13–1.19)     | 12        | <0.001  | 1.062(1.032–1.092)  | 4.148     | <0.001  |
| Sex       | 0.74(0.69–0.78)     | −9.5      | <0.001  | 0.902(0.84–0.969)   | −2.815    | 0.005   |
| Race      | 1.10(1.04–1.16)     | 3.24      | 0.0012  |                       |           |         |
| Primary   | 0.98(0.96–1.00)     | −2.09     | 0.037   | 0.977(0.957–0.998)   | −2.197    | 0.028   |
| Grade     | 1.98(1.92–2.04)     | 41.9      | <0.001  | 1.223(1.174–1.275)   | 9.563     | <0.001  |
| Behav     | 2.77(2.67–2.88)     | 53.4      | <0.001  | 1.41(1.336–1.488)    | 12.501    | <0.001  |
| Stage     | 2.21(2.17–2.25)     | 84.2      | <0.001  | 1.937(1.823–2.058)   | 21.309    | <0.001  |
| T         | 2.15(2.11–2.20)     | 78.2      | <0.001  | 1.136(1.078–1.198)   | 4.725     | <0.001  |
| N         | 2.23(2.16–2.31)     | 46.5      | <0.001  |                       |           |         |
| M         | 9.17(8.39–10.00)    | 49        | <0.001  |                       |           |         |
| Surgery   | 1.27(1.24–1.29)     | 25.6      | <0.001  | 0.909(0.884–0.935)   | −6.688    | <0.001  |
| Radiation | 0.29(0.26–0.31)     | −31.3     | <0.001  |                       |           |         |
| Chemotherapy | 0.69(0.64–0.72)   | −13       | <0.001  | 1.234(1.153–1.32)    | 6.069     | <0.001  |
| Size      | 1.57(1.53–1.61)     | 33.1      | <0.001  | 1.214(1.174–1.255)   | 11.272    | <0.001  |
| Number    | 1.12(1.05–1.18)     | 3.65      | 0.00026 | 0.916(0.858–0.978)   | −2.629    | 0.009   |
Figure 2: Continued.
In most cases, conventional survival analysis techniques only take into account the findings of one endpoint and thus might overstate or undervalue the impact of independent risk variables, which are often present in right-censored data and are commonly employed in survival analysis methods. The competitive risk model is applicable to the survival data.
Figure 3: Nomogram for predicting tumor-specific mortality in bladder cancer. (B, L, O, P, and O in primary denote bladder, NOS, lateral wall of bladder, overlapping lesion of bladder, posterior wall of bladder, and others, respectively). Papillary and transitional in behaviour denote papillary transitional cell carcinoma and transitional cell carcinoma, NOS, respectively).

Figure 4: Continued.
Figure 4: ROC curves of 1-, 3-, and 5-year cancer-specific mortality in the training cohort and validation cohort. (a, b, and c are ROC curves of 1-, 3-, and 5-year cancer-specific mortality in the training cohort, respectively; d, e, and f are ROC curves of 1-, 3-, and 5-year cancer-specific mortality in the validation cohort, respectively).

Figure 5: Continued.
of multiple endpoints. It is an analytical method to deal with the survival data of multiple potential outcomes. If the clinical survival data have multiple outcomes and the hypothesis of "deletion independence" is not satisfied when there are competitive outcomes, the Cox proportional risk model cannot be used for multifactor analysis, otherwise the wrong hazard ratio will occur. At this time, the competitive risk model reflects its unique value. However, this study has some limitations. First, the prognosis of individuals with bladder cancer is likely influenced by their lifestyle, genes, and other factors; however, the SEER database did not include information on these variables. Second, only internal validation was performed for our model. Further validation of external clinical data and future clinical applications are needed. It is expected that future studies will be conducted in order to investigate other aspects.

5. Conclusion
We constructed a competitive risk model to anticipate cancer-specific mortality in bladder cancer patients, which proved to be of great accuracy and reliability and could help clinical decision-makers improve the management and follow-up methods for these patients.

Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.

Conflicts of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.

Acknowledgments
We would like to thank the researchers and study participants for their contributions.

References
[1] H. Sung, J. Ferlay, R. L. Siegel et al., “Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” A Cancer Journal for Clinicians, vol. 71, no. 3, pp. 209–249, 2021.
[2] R. L. Siegel, K. D. Miller, H. E. Fuchs, and A. Jemal, “Cancer statistics, 2022,” A Cancer Journal for Clinicians, vol. 72, no. 1, pp. 7–33, 2022.
[3] J. A. Witjes, H. M. Bruins, R. Cathomas et al., “European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines,” European Urology, vol. 79, no. 1, pp. 82–104, 2021.
[4] A. M. Kamat, N. M. Hahn, J. A. Efstathiou et al., “Bladder cancer,” The Lancet, vol. 388, 2016.
[5] A. T. Lenis, P. M. Lec, K. Chamiie, and M. D. Msh, “Bladder cancer: a review,” Journal of the American Medical Association, vol. 324, 2020.
[6] K. Saginala, A. Barsouk, J. S. Aluru, P. Rawla, S. A. Padala, and A. Barsouk, “Epidemiology of bladder cancer,” Medical Science, vol. 8, no. 1, 2020.
[7] S. Safiri, A. A. Kolahi, and M. Naghavi, “Global, regional and national burden of bladder cancer and its attributable risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of disease study 2019,” BMJ Glob Health, vol. 6, no. 11, Article ID e004128, 2021.
[8] N. G. Zaorsky, T. M. Churilla, B. L. Egleston et al., “Causes of death among cancer patients,” Annals of Oncology, vol. 28, no. 2, pp. 400–407, 2017.
[9] X. Zhan, L. Chen, M. Jiang, and B. Fu, “Trends in the Cause of Death Among Patients with Bladder Cancer in the US SEER Population1992–2018,” World Journal of Urology, vol. 40, 2022.
[10] R. J. Sylvester, A. P. van der Meijden, W. Oosterlinck et al., “Predicting recurrence and progression in individual patients with stage T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials,” European Urology, vol. 49, no. 3, pp. 466–477, 2006.
[11] G. Verhoest, S. F. Shariat, T. F. Chromecki et al., “Predictive factors of recurrence and survival of upper tract urothelial carcinomas,” World Journal of Urology, vol. 29, no. 4, pp. 495–501, 2011.
[12] C. T. Nguyen, A. J. Stephenson, and M. W. Kattan, "Are nomograms needed in the management of bladder cancer?" Urologic Oncology: Seminars and Original Investigations, vol. 28, no. 1, pp. 102–107, 2010.

[13] P. Nuhn, M. May, M. Sun et al., "External validation of postoperative nomograms for prediction of all-cause mortality, cancer-specific mortality, and recurrence in patients with urothelial carcinoma of the bladder," European Urology, vol. 61, no. 1, pp. 58–64, 2012.

[14] M. Montalvo, E. Mistry, A. D. Chang et al., "Predicting symptomatic intracranial haemorrhage after mechanical thrombectomy: the TAG score," Journal of Neurology Neurosurgery and Psychiatry, vol. 90, no. 12, 2019.

[15] Z. R. Zhou, W. W. Wang, Y. Li et al., "In-depth mining of clinical data: the construction of clinical prediction model with R," Annals of Translational Medicine, vol. 7, no. 23, p. 796, 2019.

[16] X. Zhan, T. Chen, M. Jiang et al., "A novel nomogram and risk classification system predicting the cancer-specific survival of muscle-invasive bladder cancer patients after partial cystectomy," Journal of the American Medical Association Oncology, vol. 2022, Article ID 2665711, 10 pages, 2022.

[17] Z. Yang, Y. Bai, M. Liu, X. Hu, and P. Han, "Development and validation of a prognostic nomogram for predicting cancer-specific survival in patients with lymph node positive bladder cancer: a study based on SEER database," Frontiers in Oncology, vol. 12, 2022.

[18] L. Tao, X. Pan, L. Zhang et al., "Marital status and prognostic nomogram for bladder cancer with distant metastasis: a SEER-based study," Frontiers in Oncology, vol. 10, 2020.

[19] Z. Wang, Y. Zhou, C. Guan et al., "The impact of previous cancer on overall survival of bladder cancer patients and the establishment of nomogram for overall survival prediction," Medicine (Baltimore), vol. 99, no. 38, 2020.

[20] Z. Yang, Y. Bai, M. Liu, X. Hu, and P. Han, "Development and validation of a prognostic nomogram for predicting cancer-specific survival after radical cystectomy in patients with bladder cancer: a population-based study," Cancer Medicine, vol. 9, no. 24, 2020.

[21] J. Wang, Y. Wu, W. He, B. Yang, and X. Gou, "Nomogram for predicting overall survival of patients with bladder cancer: a population-based study," The International Journal of Biological Markers, vol. 35, no. 2, pp. 29–39, 2020.

[22] W. Wang, J. Liu, and L. Liu, "Development and validation of a prognostic model for predicting overall survival in patients with bladder cancer: a SEER-based study," Frontiers in Oncology, vol. 11, 2021.

[23] J. Wu, J. Z. Shou, and Y. C. Wang, "Survival analysis of lymphoepithelioma-like carcinoma of the urinary bladder and the effect of surgical treatment modalities on prognosis," Front Surg, vol. 8, 2021.

[24] H. Lu, W. Zhu, W. Mao et al., "Trends of incidence and prognosis of primary adenocarcinoma of the bladder," Therapeutic Advances in Urology, vol. 13, 2021.

[25] E. Tracey, D. Roder, C. Luke, and J. Bishop, "Bladder cancer survivals in New South Wales, Australia: why do women have poorer survival than men?" BJU International, vol. 104, no. 4, pp. 498–504, 2009.

[26] D. Tilki, O. Reich, R. S. Svatek et al., "Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients," The Journal of Urology, vol. 183, no. 5, 2010.

[27] G. Wang and J. K. McKenney, "Urinary bladder pathology: World health organization classification and American joint committee on cancer staging update," Archives of Pathology and Laboratory Medicine, vol. 143, no. 5, pp. 571–577, 2019.

[28] J. Shou, Q. Zhang, and D. Zhang, "The prognostic effect of metastasis patterns on overall survival in patients with distant metastatic bladder cancer: a SEER population-based analysis," World Journal of Urology, vol. 39, no. 11, 2021.

[29] F. Dong, Y. Shen, F. Gao et al., "Prognostic value of site-specific metastases and therapeutic roles of surgery for patients with metastatic bladder cancer: a population-based study," Cancer Management and Research, vol. 9, pp. 611–626, 2017.

[30] M. Abudurexiti, J. Ma, Y. Li et al., "Clinical outcomes and prognosis analysis of younger bladder cancer patients," Current Oncology, vol. 29, no. 2, pp. 578–588, 2022.